Search hospitals > Tennessee > Knoxville
East Tennessee Childrens Hospital
Claim this profileKnoxville, Tennessee 37916
Global Leader in Uterine Tumors
Global Leader in T-Lymphoblastic Leukemia/Lymphoma
Conducts research for Cancer
Conducts research for Lymphoma
Conducts research for Brain Tumor
211 reported clinical trials
2 medical researchers
Summary
East Tennessee Childrens Hospital is a medical facility located in Knoxville, Tennessee. This center is recognized for care of Uterine Tumors, T-Lymphoblastic Leukemia/Lymphoma, Cancer, Lymphoma, Brain Tumor and other specialties. East Tennessee Childrens Hospital is involved with conducting 211 clinical trials across 339 conditions. There are 2 research doctors associated with this hospital, such as Susan E. Spiller and Ray C. Pais.Area of expertise
1Uterine Tumors
Global LeaderStage IV
Stage I
Stage II
2T-Lymphoblastic Leukemia/Lymphoma
Global LeaderStage II
Philadelphia chromosome positive
BCR-ABL1 fusion positive
Top PIs
Susan E. SpillerEast Tennessee Childrens Hospital7 years of reported clinical research
Expert in Cancer
Expert in Uterine Tumors
51 reported clinical trials
109 drugs studied
Ray C. PaisEast Tennessee Childrens Hospital19 years of reported clinical research
Studies T-Lymphoblastic Leukemia/Lymphoma
Studies Leukemia
8 reported clinical trials
30 drugs studied
Clinical Trials running at East Tennessee Childrens Hospital
Acute Lymphoblastic Leukemia
Testicular cancer
T-Lymphoblastic Leukemia/Lymphoma
Acute Myeloid Leukemia
Lymphoma
Ovarian Tumors
Ovarian Choriocarcinoma
Ovarian Carcinoma
Low Grade Glioma
Rhabdomyosarcoma
Levocarnitine
for Chemotherapy-Related Liver Protection in Leukemia and Lymphoma
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often prevents delivery of planned chemotherapy, thereby potentially compromising outcomes. Some groups of people may also be at higher risk for liver damage due to the presence of fat in the liver even before starting chemotherapy. Patients who are of Japanese descent, Native Hawaiian, Hispanic or Latinx may be at greater risk for liver damage from chemotherapy for this reason. Carnitine is a naturally occurring nutrient that is part of a typical diet and is also made by the body. Carnitine is necessary for metabolism and its deficiency or absence is associated with liver and other organ damage. Levocarnitine is a drug used to provide extra carnitine. Laboratory and real-world usage of the dietary supplement levocarnitine suggests its potential to prevent or reduce liver toxicity from asparaginase. The overall goal of this study is to determine whether adding levocarnitine to standard of care chemotherapy will reduce the chance of developing severe liver damage from asparaginase chemotherapy in ALL, LL and/or MPAL patients.
Recruiting2 awards Phase 3
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
Blinatumomab + Nivolumab
for Acute Lymphoblastic Leukemia
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occurs which may kill the cancer cell. Nivolumab is a medicine that may boost a patient's immune system. Giving nivolumab in combination with blinatumomab may cause the cancer to stop growing for a period of time, and for some patients, it may lessen the symptoms, such as pain, that are caused by the cancer.
Recruiting1 award Phase 28 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at East Tennessee Childrens Hospital?
East Tennessee Childrens Hospital is a medical facility located in Knoxville, Tennessee. This center is recognized for care of Uterine Tumors, T-Lymphoblastic Leukemia/Lymphoma, Cancer, Lymphoma, Brain Tumor and other specialties. East Tennessee Childrens Hospital is involved with conducting 211 clinical trials across 339 conditions. There are 2 research doctors associated with this hospital, such as Susan E. Spiller and Ray C. Pais.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.